EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends

Yodit Girmay iD, Francesca Portelli, Rasmus Mikiver, Jan Lapins iD, Karolin Isaksson, Hildur Helgadottir iD

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.20522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Yodit Girmay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research Funds of Radiumhemmet, Region Stockholm, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Desmoplastic melanoma (DM) is a rare subtype, accounting for less than 5% of primary cutaneous invasive melanomas. DM often arises in chronically sun‐exposed skin, in older individuals. While the incidence of cutaneous melanoma has increased globally, trends specific to DM are less documented and studies on survival outcomes for DM are inconsistent.

Objectives

To study patient and tumour characteristics, incidence trends and survival outcomes of desmoplastic melanoma in comparison with other melanoma subtypes using data from the population‐based Swedish Melanoma Registry (SweMR).

Methods

Clinicopathological variables were obtained from SweMR, for patients diagnosed with invasive cutaneous melanomas diagnosed in Sweden from 2009 to 2022. Incidence rates of DM per 100,000 inhabitants were calculated. DM cases were identified and survival outcomes were compared across DM, superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo maligna melanoma (LMM). Survival was analysed using Kaplan–Meier and Cox regression methods.

Results

Among 48,945 invasive melanomas, 388 (0.8%) were identified as DM. The incidence ranged between 0.1 and 0.4 cases per 100,000, without a evident rise, beside a certain peak in 2019–2020 in the men. DM had compared to other melanoma subtypes the thickest primary tumours ( p < 0.001). When adjusting for baseline prognostic factors, DM patients had an improved melanoma‐specific survival (HR 0.36, 95% CI 0.26–0.49). No significant improvement in survival was observed for DM diagnosed in 2015–2022 compared to those diagnosed in 2009–2014 (adjusted HR 0.99, 95% CI 0.45–2.14), whereas other subtypes showed an improvement (adjusted HR 0.74, 95% CI 0.68–0.80).

Conclusions

In contrast to the rising incidence of other melanoma subtypes, the incidence of DM has remained more stable over recent years. Despite presenting with adverse prognostic features, survival from DM is superior when adjusting for these factors. However, the introduction of anti‐PD‐1 therapy has not significantly improved survival for DM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansSwedenMaleIncidenceRegistriesFemaleAgedMiddle AgedAdultAged, 80 and overCutaneous Malignant MelanomaSurvival RateYoung Adult

Autor:innen und Institutionen

  • Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
  • Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.
  • Dermatology and Venereology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Sciences, Surgery, Lund University, Lund, Sweden.

ORCID-Profile: Yodit Girmay, Jan Lapins, Hildur Helgadottir

Förderung

  • Cancer Research Funds of Radiumhemmet
  • Region Stockholm
  • Cancerfonden

Zitieren

APA

Girmay, Y., Portelli, F., Mikiver, R., Lapins, J., Isaksson, K., & Helgadottir, H. (2026). Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20522

Vancouver

Girmay Y, Portelli F, Mikiver R, Lapins J, Isaksson K, Helgadottir H. Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.20522

BibTeX
@article{Girmay2026,
  author = {Girmay, Yodit and Portelli, Francesca and Mikiver, Rasmus and Lapins, Jan and Isaksson, Karolin and Helgadottir, Hildur},
  title = {Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.20522}
}
Kostenlos starten →